Bausch Health Suspends IPO of Solta Due to Market Conditions

This post was originally published on this site

According to the company, Solta will remain as part of Bausch Health as it believes the interests of the company’s stakeholders are best served in the near term by focusing on driving Solta’s revenue, profits, and cash flow while also achieving key operational and regulatory milestones.

Bausch Health will revisit alternative paths for Solta in the future.

By Davit Kirakosyan